Approval of the topical aryl hydrocarbon receptor agonist was supported by the pivotal ADORING studies. In the ...

In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for ...

Atopic dermatitis in infancy is associated with an increased risk of developing subsequent atopic march conditions such as allergy or asthma.

Current dermatological guidelines now recognize crisaborole two percent ointment as a potential first-line treatment option ...

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to ...

Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing ...

The approval was based on data from 2 multicenter, randomized, double-blind, vehicle-controlled trials, ADORING 1 and ADORING 2.

A total of 5 distinct atopic dermatitis phenotypes and associated characteristics were identified among children using multi-omics profiling.

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...